Table 1:
Patient characteristics
| Total patients (%) | Data site patients (%) | Testing site patients (%) | |
|---|---|---|---|
| N =1378 | N=736 | N=642 | |
| Age at switch to second-line ART (years) | Median =37, IQR (32–42) | Median =39, IQR (34–44.5) | Median =44, IQR (30–39) |
| ≤30 | 290 (21) | 113 (15) | 177 (28) |
| 31–40 | 645 (47) | 316 (43) | 329 (51) |
| 41–50 | 337 (24) | 231 (31) | 106 (17) |
| >50 | 106 (8) | 76 (10) | 30 (5) |
| Duration on second line ART (years) | Median = 3, IQR (1–5) | Median = 2, IQR (1–5) | Median = 3, IQR (2–6) |
| Sex | |||
| Male | 1023 (74) | 570 (77) | 453 (71) |
| Female | 355 (26) | 166 (23) | 189 (29) |
| HIV mode of exposure | |||
| Heterosexual contact | 964 (70) | 570 (77) | 394 (61) |
| Male-male sex | 134 (10) | 91 (12) | 43 (7) |
| Injecting drug use | 172 (12) | 5 (1) | 167 (26) |
| Other/Unknown | 108 (8) | 70 (10) | 38 (6) |
| CD4 at switch to second-line (cells/μL) | Median =103, IQR (43.5–229.5) | Median =178.5, IQR (70–306) | Median =67.5, IQR (27–149) |
| ≤50 | 298 (22) | 81 (11) | 217 (34) |
| 51–100 | 209 (15) | 73 (10) | 136 (21) |
| 101–200 | 217 (16) | 108 (15) | 109 (17) |
| >200 | 304 (22) | 210 (29) | 94 (15) |
| Not reported | 350 (25) | 264 (36) | 86 (13) |
| Second-line ART Regimen | |||
| NRTI+PI | 1281 (93) | 653 (89) | 628 (98) |
| Integrase inhibitor combination | 78 (6) | 74 (10) | 4 (1) |
| Other combination | 19 (1) | 9 (1) | 10 (2) |
| Reason for switching to second-line ART | |||
| Virologic failure only | 873 (63) | 687 (93) | 186 (29) |
| Immunologic failure only | 51 (4) | 11 (1) | 40 (6) |
| Virologic and immunologic failure | 221 (16) | 17 (2) | 204 (32) |
| *Other reasons | 233 (17) | 21 (3) | 212 (33) |
| World Bank country income group | |||
| Lower + upper middle | 1267 (92) | 625 (85) | 642 (100) |
| High | 111 (8) | 111 (16) | 0 (0) |
NRTI: Nucleoside Reverse Transcriptase Inhibitor; PI: Protease Inhibitor
*
Other reasons include clinical failure only; virologic and clinical failure; immunologic and clinical failure; and virologic, immunologic and clinical failure